Press coverage about vTv Therapeutics (NASDAQ:VTVT) has been trending somewhat positive on Saturday, Accern Sentiment reports. Accern scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. vTv Therapeutics earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 44.9374093065625 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
vTv Therapeutics (NASDAQ:VTVT) traded up $0.09 on Friday, hitting $5.70. The stock had a trading volume of 119,406 shares, compared to its average volume of 413,536. vTv Therapeutics has a 52 week low of $3.57 and a 52 week high of $8.09. The stock has a market cap of $190.03 and a P/E ratio of -3.48.
vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.38) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.40) by $0.02. sell-side analysts predict that vTv Therapeutics will post -1.65 earnings per share for the current year.
Several equities research analysts recently issued reports on VTVT shares. Canaccord Genuity set a $15.00 price objective on vTv Therapeutics and gave the stock a “buy” rating in a research note on Thursday, December 21st. Zacks Investment Research downgraded vTv Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, September 29th. Stifel Nicolaus reissued a “buy” rating and issued a $12.00 price objective on shares of vTv Therapeutics in a research note on Friday, November 3rd. Finally, Citigroup reaffirmed an “add” rating on shares of vTv Therapeutics in a research note on Wednesday, November 8th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. vTv Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $14.10.
In related news, Director Paul G. Savas acquired 15,000 shares of the stock in a transaction dated Thursday, December 7th. The shares were acquired at an average price of $4.56 per share, with a total value of $68,400.00. Following the acquisition, the director now owns 81,781 shares in the company, valued at approximately $372,921.36. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Ronald O. Perelman acquired 50,000 shares of the stock in a transaction dated Tuesday, December 26th. The shares were bought at an average cost of $4.03 per share, for a total transaction of $201,500.00. The disclosure for this purchase can be found here. Corporate insiders own 0.80% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/21/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-vtv-therapeutics-vtvt-share-price.html.
About vTv Therapeutics
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.